8-K: GRI Bio's GRI-0621 Shows Strong IPF Gene Expression Data

GRI Bio announced additional positive Phase 2a clinical data for GRI-0621 in Idiopathic Pulmonary Fibrosis, demonstrating significant improvements in gene expression related to fibrosis and lung repair.

Summary

• GRI Bio announced additional positive data from its Phase 2a clinical study of GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF).
• New RNA-sequencing differential gene expression data show GRI-0621 treatment significantly improved genes associated with lung injury, myofibroblast activation, extracellular matrix deposition, fibrosis progression, and alveolar basement membrane and epithelial repair compared to placebo.
• These findings independently validate previously reported biomarker, functional, and clinical signals from the Phase 2a study.
• GRI-0621 modulated genes linked to key drivers of IPF, supporting a mechanism consistent with fibrosis resolution and active tissue repair.
• The treatment favorably modulated differentially expressed genes (DEGs) associated with lung injury, myofibroblast activation, and excessive extracellular matrix (ECM) deposition.
• This aligns with earlier biomarker data showing decreased neutrophil activity (CPa9-HNE), increased degradation and reduced synthesis of fibrillar collagens (Type III and Type VI), and lower levels of pro-fibrotic cytokines (IL-4, IL-13, TGF-1).
• The data directly support basement membrane repair and AT2-to-AT1 epithelial cell transition, key hallmarks of lung regeneration.
• The Phase 2a study met its primary endpoint, demonstrating favorable safety and tolerability and multiple secondary endpoints for disease-modifying activity.
• Improvements were observed on the exploratory endpoint of forced vital capacity (FVC), with twice as many GRI-0621-treated subjects experiencing no decline in FVC at 12 weeks compared to standard of care alone.

Sentiment

Score: 9

Explanation: The filing presents highly positive clinical trial data, indicating strong potential for GRI-0621 to be a disease-modifying therapy for IPF, with a favorable safety profile and evidence of lung regeneration. The convergence of multiple data points (gene expression, biomarkers, functional) strengthens the proof-of-concept.

Positives

• GRI-0621 treatment resulted in significant improvement across genes associated with lung injury, myofibroblast activation, extracellular matrix deposition, fibrosis progression, and alveolar basement membrane and epithelial repair.
• The gene expression data provide powerful, independent validation of previously reported biomarker, functional, and clinical signals.
• GRI-0621 directly impacts the core biology of IPF, supporting fibrosis resolution and active tissue repair.
• Favorable modulation of differentially expressed genes (DEGs) associated with lung injury, myofibroblast activation, and excessive extracellular matrix (ECM) deposition.
• Convergence of gene expression, serum biomarkers (decreased neutrophil activity, increased collagen degradation, lower pro-fibrotic cytokines), and immune phenotypes provides multi-layered evidence of direct targeting of fibrosis drivers.
• Data support regeneration of lung architecture, including basement membrane repair and AT2-to-AT1 epithelial cell transition, suggesting true lung regeneration.
• The Phase 2a study met its primary endpoint, demonstrating favorable safety and tolerability.
• Met multiple secondary endpoints indicative of disease-modifying activity.
• Showed improvements on the exploratory endpoint of forced vital capacity (FVC), with twice as many GRI-0621-treated subjects experiencing no decline in FVC at 12 weeks compared to standard of care alone.
• GRI-0621 has a well-tolerated safety profile, differentiating it from existing treatments with significant side-effect burdens.

Risks

• Inability to maintain listing on The Nasdaq Capital Market and comply with applicable listing requirements.
• Changes in applicable laws or regulations.
• Inability to raise financing in the future.
• Uncertainty regarding the success, cost, and timing of product development activities.
• Inability to obtain and maintain regulatory clearance or approval for products, and any related restrictions and limitations of any cleared or approved product.
• Inability to identify, in-license, or acquire additional technology.
• Inability to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently developing.
• Uncertainty regarding the size and growth potential of the markets for the Company's products and services, and their respective ability to serve those markets, either alone or in partnership with others.
• Later data or clinical trials may be inconsistent with or contrary to data and observations to date, including that later data may not indicate a proof-of-concept or patient benefit.
• Inaccuracy in the Company's estimates regarding expenses, future revenue, capital requirements, and needs for and the ability to obtain additional financing.
• The Company's ability to protect and enforce its intellectual property portfolio, including any newly issued patents and its ability to obtain any expected patent term extensions, adjustments, exclusivities, or disclaimers.
• Other risks and uncertainties indicated from time to time in the Company's filings with the U.S. Securities and Exchange Commission (the SEC), including the risks and uncertainties described in the Risk Factors section of the Company's most recent Annual Report on Form 10-K filed with the SEC on March 14, 2025 and subsequently filed reports.

Future Outlook

The Company plans to submit the new gene expression findings for presentation at a major medical conference. GRI Bio believes GRI-0621 has the potential to alter the trajectory of IPF by promoting repair of damaged lung tissue, representing a fundamentally different approach compared to existing treatments. The company is also developing a pipeline of novel type 2 diverse NKT (dNKT) agonists for systemic lupus erythematosus and has a library of over 500 proprietary compounds to fuel future pipeline growth.

Management Comments

• "Across gene expression, serum biomarkers, immune profiles and lung function, we see a remarkably consistent picture emerge. GRI-0621 appears to suppress ongoing injury, reduce fibrosis, and activate mechanisms associated with rebuilding damaged lung tissue." Marc Hertz, PhD, CEO of GRI Bio.
• "The totality of data generated in this Phase 2a study suggests that GRI-0621 may represent a fundamentally different approach, with the potential to alter the trajectory of disease by promoting repair of damaged lung tissue." Marc Hertz, PhD, CEO of GRI Bio.

Industry Context

Idiopathic Pulmonary Fibrosis (IPF) is a serious disease with significant unmet medical need. Existing treatment options primarily slow disease decline but carry significant side-effect burdens. GRI-0621, by targeting NKT cells and promoting lung repair and regeneration, could represent a differentiated and potentially disease-modifying therapy, offering a new paradigm beyond symptomatic management. This positions GRI Bio as a potential innovator in the inflammatory and fibrotic disease space.

Comparison to Industry Standards

• Existing IPF treatments primarily focus on slowing disease progression and are associated with significant side effects.
• GRI-0621's observed effects, including suppressing ongoing injury, reducing fibrosis, and activating mechanisms associated with rebuilding damaged lung tissue, suggest a potential for true lung regeneration, which differentiates it from current standard of care.
• The well-tolerated safety profile of GRI-0621 contrasts with the significant side-effect burdens of current treatment options.
• The improvement in forced vital capacity (FVC), with twice as many GRI-0621-treated subjects experiencing no decline at 12 weeks compared to standard of care alone, indicates a potentially superior functional benefit.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical data, potential for a differentiated and disease-modifying therapy, and validation of the company's pipeline. This could lead to increased investor confidence and potential share price appreciation.
• Patients with IPF: Significant positive impact as GRI-0621 shows potential for true lung regeneration and a better safety profile compared to existing treatments, addressing a high unmet medical need.
• Medical Community: The data suggests a novel approach to treating IPF, potentially influencing future treatment paradigms and research.
• Employees: Positive impact from successful clinical development, potentially leading to increased job security and opportunities.

Next Steps

• Submit new gene expression findings for presentation at a major medical conference.
• Continue development of GRI-0621 for Idiopathic Pulmonary Fibrosis.
• Develop a pipeline of novel type 2 diverse NKT (dNKT) agonists for systemic lupus erythematosus.
• Utilize the library of over 500 proprietary compounds to fuel pipeline growth.

Key Dates

Recommendation

The additional Phase 2a data for GRI-0621 in IPF are exceptionally strong, demonstrating not just a slowing of disease but evidence of lung repair and regeneration, which is a significant differentiator from current therapies. The convergence of gene expression, biomarker, and functional data provides robust proof-of-concept. Combined with a favorable safety profile and unmet medical need in IPF, this positions GRI-0621 as a potentially transformative therapy. This positive clinical development significantly de-risks the asset and enhances the company's long-term value proposition, warranting a strong buy recommendation for investors seeking exposure to innovative biotechnology with high growth potential.

Keywords

Idiopathic Pulmonary Fibrosis, IPF, GRI-0621, Phase 2a clinical trial, gene expression, fibrosis, lung repair, biotechnology, immune cell modulators, NKT cells, RAR agonist, clinical data, biomarkers, FVC